As a former CEO-in-Residence with BioEnterprise, Stephen Charles advised and supported biopharmaceutical companies, including Diasome Pharmaceuticals, a company focused on clinical and commercial breakthrough therapies for diabetes and obesity. In 2016, Charles joined Diasome, where he now the Chief Technology Officer. Prior to BioEnterprise, Charles founded Oligasis, a biopharmaceutical company developing treatments for retinal diseases, and played key development roles in multiple successful, long-lived, marketed product platforms: J&J Ortho’s Vitros central laboratory diagnostic system; GE Healthcare’s Biacore biosensor; CooperVision’s Proclear range of contact lenses; Medtronic’s Endeavor drug-eluting coronary stent; and several PEGylated biopharmaceutical products. Charles earned his B.Sc. and Ph.D. degrees in biochemistry from the University of London.